AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Helix BioPharma Corp.
Video analysis: HBPCF
All videosNo video analysis for this stock yet. Request one from our team.
News: HBPCF
Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
Vancouver, British Columbia – TheNewswire - August 17, 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPC F ” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers , today announced the appointment of Markus Loeffler, MD, MBA as Chief Medical Officer (CMO) of the Company. Dr. Loeffler's appointment comes as Helix prepares to enter a more execution-focused phase of clinical development, with multiple programs approaching key regulatory and clinical milestones. As CMO, he will lead the strategy and execution of Helix's clinical programs, including the planned Phase Ib/II evaluation of L-DOS47 in combination with pembrolizumab in first-line non-small cell lung cancer (NSCLC), while guiding LEUMUNA™ toward clinical development for leukemia relapse following allogeneic stem cell transplantation.
Helix Biopharma Corp. Announces Board Composition Changes
Vancouver, British Columbia; August 14, 2026 – TheNewswire - Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers , today announced changes to its Board of Directors (the “Board” ), effective immediately. Mr. Janusz Grabski has resigned from Helix's Board, with immediate effect. Concurrently, the Board has formally appointed Thomas Mehrling, M.D., Ph.D., Helix's Chief Executive Officer, as a director of the Company, pursuant to the Board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG. 1
Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
Vancouver, British Columbia – TheNewswire - June 30 , 2026 – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are vincible, today announced the appointments of Helen Middleton as General Counsel and David Browning as Vice President of Clinical Operations . The appointments further strengthen Helix's executive leadership team as the Company prepares for its planned U.S. securities exchange listing, advances the next stage of development for L-DOS47 through LDOS007, the Company's planned Phase IB/Randomized Phase II study in first-line non-small cell lung cancer (NSCLC), and continues building the legal, governance and operational infrastructure required to support its next phase of growth. “The next stage of Helix's evolution demands a different kind of company than the one we were building two years ago,” said Thomas Mehrling, MD, PhD, Chief Executive Officer of the Company. “As we prepare for our planned U.S. securities exchange listing and advance L-DOS47 into its next stage of clinical development, we are deliberately strengthening every part of the organization. From our legal and governance framework to our clinical execution capabilities, we are building the leadership team required to support the next phase of Helix's growth.”
Similar companies
-
MindMaze Therapeutics Holding S.A.
RLFTY
·
Other OTC
Compare
-
Clara Technologies Corp.
CLTEF
·
Other OTC
Compare
-
PsyBio Therapeutics Corp
PSYBF
·
Other OTC
Compare
-
Arch Biopartners Inc.
ACHFF
·
Other OTC
Compare
-
Amplia Therapeutics Limited
INNMF
·
Other OTC
Compare
-
ZIVO Bioscience, Inc.
ZIVO
·
Other OTC
Compare